HRP20161429T1 - Farmaceutski sastav - Google Patents
Farmaceutski sastav Download PDFInfo
- Publication number
- HRP20161429T1 HRP20161429T1 HRP20161429TT HRP20161429T HRP20161429T1 HR P20161429 T1 HRP20161429 T1 HR P20161429T1 HR P20161429T T HRP20161429T T HR P20161429TT HR P20161429 T HRP20161429 T HR P20161429T HR P20161429 T1 HRP20161429 T1 HR P20161429T1
- Authority
- HR
- Croatia
- Prior art keywords
- range
- present
- mass percent
- pharmaceutical composition
- oral pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67280505P | 2005-04-19 | 2005-04-19 | |
| PCT/US2006/014447 WO2006113649A1 (en) | 2005-04-19 | 2006-04-18 | Pharmaceutical composition |
| EP06750475.3A EP1871347B1 (en) | 2005-04-19 | 2006-04-18 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161429T1 true HRP20161429T1 (hr) | 2016-12-16 |
Family
ID=37115487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161429TT HRP20161429T1 (hr) | 2005-04-19 | 2006-04-18 | Farmaceutski sastav |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8821927B2 (enExample) |
| EP (1) | EP1871347B1 (enExample) |
| JP (1) | JP5202302B2 (enExample) |
| KR (1) | KR101356748B1 (enExample) |
| CN (1) | CN101203211B (enExample) |
| AR (1) | AR054252A1 (enExample) |
| AU (1) | AU2006236423B2 (enExample) |
| BR (1) | BRPI0609962B1 (enExample) |
| CA (1) | CA2606207C (enExample) |
| CY (1) | CY1118179T1 (enExample) |
| DK (1) | DK1871347T3 (enExample) |
| EA (1) | EA200702253A1 (enExample) |
| ES (1) | ES2601503T3 (enExample) |
| HR (1) | HRP20161429T1 (enExample) |
| HU (1) | HUE030982T2 (enExample) |
| IL (1) | IL186336A0 (enExample) |
| LT (1) | LT1871347T (enExample) |
| MA (1) | MA29404B1 (enExample) |
| MX (1) | MX2007013089A (enExample) |
| NO (1) | NO20075111L (enExample) |
| NZ (1) | NZ562223A (enExample) |
| PE (1) | PE20061430A1 (enExample) |
| PL (1) | PL1871347T3 (enExample) |
| PT (1) | PT1871347T (enExample) |
| SI (1) | SI1871347T1 (enExample) |
| TW (1) | TW200716204A (enExample) |
| WO (1) | WO2006113649A1 (enExample) |
| ZA (1) | ZA200708705B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200716204A (en) * | 2005-04-19 | 2007-05-01 | Smithkline Beecham Cork Ltd | Pharmaceutical composition |
| US8252805B2 (en) | 2008-05-07 | 2012-08-28 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
| EP2158912A1 (en) * | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
| EP2158913A1 (en) | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
| WO2010099150A1 (en) * | 2009-02-24 | 2010-09-02 | Smithkline Beecham (Cork) Limited | Pharmaceutical tablet and process |
| US20120245351A1 (en) * | 2009-09-29 | 2012-09-27 | Natco Pharma Limited | Process for the preparation of lapatinib and its pharmaceutically acceptable salts |
| JP5858989B2 (ja) | 2010-05-21 | 2016-02-10 | ノバルティス アーゲー | 組合せ |
| JP2013526578A (ja) | 2010-05-21 | 2013-06-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 組合せ |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| KR20180008918A (ko) | 2010-08-03 | 2018-01-24 | 앨씨알엑스, 인크. | 과민성 방광 치료를 위한 베타-3 아드레날린 수용체 작용제 및 무스카린 수용체 길항제의 약학적 배합제 |
| EA029119B1 (ru) * | 2013-02-19 | 2018-02-28 | Хексаль Аг | Фармацевтическая композиция, содержащая n-[3-хлор-4-(3-фторбензилокси)фенил]-6-[5({[2-(метилсульфонил)этил]амино}метил)-2-фурил]хиназолин-4-амин или его фармацевтически приемлемые соль, сольват или сольватированную соль |
| WO2014170910A1 (en) | 2013-04-04 | 2014-10-23 | Natco Pharma Limited | Process for the preparation of lapatinib |
| US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
| CN107205964A (zh) | 2014-12-03 | 2017-09-26 | 威力塞帕特治疗股份有限公司 | 使用调节释放索拉贝隆用于下尿路症状的组合物和方法 |
| CN106389373B (zh) * | 2015-07-29 | 2019-07-02 | 四川科伦药物研究院有限公司 | 一种二甲苯磺酸拉帕替尼片剂及其制备方法 |
| CN106511289A (zh) * | 2015-09-10 | 2017-03-22 | 湖北生物医药产业技术研究院有限公司 | 甲苯磺酸拉帕替尼片剂及其制备方法 |
| WO2017070689A2 (en) | 2015-10-23 | 2017-04-27 | Velicept Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| NZ336233A (en) | 1997-04-25 | 2001-01-26 | Janssen Pharmaceutica Nv | Phenyl substituted quinazolines on 4-position and 2-quinazolinone moiety bearing a carbon or nitrogen-linked imidazolyl moiety |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| AU7307101A (en) * | 2000-06-30 | 2002-01-14 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| WO2002056912A2 (en) | 2001-01-16 | 2002-07-25 | Glaxo Group Limited | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent |
| EP1492568A1 (en) | 2002-04-08 | 2005-01-05 | SmithKline Beecham Corporation | Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor |
| US20060094068A1 (en) | 2002-06-19 | 2006-05-04 | Bacus Sarah S | Predictive markers in cancer therapy |
| TW200716204A (en) * | 2005-04-19 | 2007-05-01 | Smithkline Beecham Cork Ltd | Pharmaceutical composition |
-
2006
- 2006-04-18 TW TW095113811A patent/TW200716204A/zh unknown
- 2006-04-18 JP JP2008507783A patent/JP5202302B2/ja active Active
- 2006-04-18 EP EP06750475.3A patent/EP1871347B1/en active Active
- 2006-04-18 WO PCT/US2006/014447 patent/WO2006113649A1/en not_active Ceased
- 2006-04-18 KR KR1020077026740A patent/KR101356748B1/ko active Active
- 2006-04-18 DK DK06750475.3T patent/DK1871347T3/en active
- 2006-04-18 HR HRP20161429TT patent/HRP20161429T1/hr unknown
- 2006-04-18 NZ NZ562223A patent/NZ562223A/en not_active IP Right Cessation
- 2006-04-18 PT PT67504753T patent/PT1871347T/pt unknown
- 2006-04-18 AU AU2006236423A patent/AU2006236423B2/en not_active Revoked
- 2006-04-18 PE PE2006000406A patent/PE20061430A1/es not_active Application Discontinuation
- 2006-04-18 AR AR20060101526A patent/AR054252A1/es not_active Application Discontinuation
- 2006-04-18 CA CA2606207A patent/CA2606207C/en active Active
- 2006-04-18 LT LTEP06750475.3T patent/LT1871347T/lt unknown
- 2006-04-18 MX MX2007013089A patent/MX2007013089A/es active IP Right Grant
- 2006-04-18 ES ES06750475.3T patent/ES2601503T3/es active Active
- 2006-04-18 EA EA200702253A patent/EA200702253A1/ru unknown
- 2006-04-18 CN CN2006800219417A patent/CN101203211B/zh active Active
- 2006-04-18 HU HUE06750475A patent/HUE030982T2/en unknown
- 2006-04-18 PL PL06750475T patent/PL1871347T3/pl unknown
- 2006-04-18 SI SI200632109A patent/SI1871347T1/sl unknown
- 2006-04-18 US US11/911,843 patent/US8821927B2/en active Active
- 2006-04-18 BR BRPI0609962-9A patent/BRPI0609962B1/pt active IP Right Grant
-
2007
- 2007-10-07 IL IL186336A patent/IL186336A0/en unknown
- 2007-10-09 NO NO20075111A patent/NO20075111L/no not_active Application Discontinuation
- 2007-10-11 ZA ZA200708705A patent/ZA200708705B/xx unknown
- 2007-10-25 MA MA30318A patent/MA29404B1/fr unknown
-
2014
- 2014-07-28 US US14/444,637 patent/US20140335177A1/en not_active Abandoned
-
2016
- 2016-01-29 US US15/009,927 patent/US20160143909A1/en not_active Abandoned
- 2016-11-03 CY CY20161101115T patent/CY1118179T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161429T1 (hr) | Farmaceutski sastav | |
| RU2485942C2 (ru) | Бупропиона гидробромид и его терапевтические применения | |
| RU2009127302A (ru) | Способ изготовления твердого, орально применимого фармацевтического состава | |
| NO20091501L (no) | Farmasoytiske sammensetninger | |
| HRP20211862T1 (hr) | Pripravci za i postupci liječenja anemije | |
| JP2008536931A5 (enExample) | ||
| SI2821067T1 (en) | Quick spray formulation of cinacalcet | |
| HRP20250383T1 (hr) | Tablete koje sadrže eltrombopag olamin | |
| FI2049506T4 (fi) | Lääkkeellisten aineiden farmakokineettisten ominaisuuksien modulaattorit | |
| JP2009545560A5 (enExample) | ||
| BG105061A (bg) | Ентерично покрит фармацевтичен състав и метод за получаване | |
| NO20084065L (no) | Hurtig frigivelses paracetamol tabletter | |
| HRP20120068T1 (hr) | Formulacija tablete s odgođenim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu sol | |
| HRP20240564T1 (hr) | Novi farmaceutski sastav | |
| CA2406373A1 (en) | Controlled release paracetamol composition | |
| HRP20120957T1 (hr) | Stabilni farmaceutski sastav koji sadrži pirimidin-sulfamid | |
| RU2008137766A (ru) | Твердые дозированные формы | |
| CY1111939T1 (el) | Φαρμακευτικο στερεο παρασκευασμα που περιλαμβανει βενζαζεπινες και μεθοδος παρασκευης αυτου | |
| RU2002108877A (ru) | Стабильный фармацевтический состав, содержащий мексидол | |
| ATE533476T1 (de) | Komprimierte pharmazeutische zusammensetzung mit beschichteten pellets und direktes kompressionsgemisch und herstellungsverfahren dafür | |
| NO20062082L (no) | Pellets inneholdende venlafaksinhydroklorid | |
| JP2019504024A5 (enExample) | ||
| JP2008515980A5 (enExample) | ||
| JP2011516544A5 (enExample) | ||
| JP2010521437A5 (enExample) |